Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group

S. Daw, D. Hasenclever, M. Mascarin, A. Fernández-Teijeiro, W. Balwierz, A. Beishuizen, R. Burnelli, M. Cepelova, A. Claviez, K. Dieckmann, J. Landman-Parker, R. Kluge, D. Körholz, C. Mauz-Körholz, WH. Wallace, T. Leblanc,

. 2020 ; 4 (1) : e329. [pub] 20200110

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005156

The objective of this guideline is to aid clinicians in making individual salvage treatment plans for pediatric and adolescent patients with first relapse or refractory (R/R) classical Hodgkin lymphoma (cHL). While salvage with standard dose chemotherapy followed by high dose chemotherapy and autologous stem cell transplant is often considered the standard of care in adult practice, pediatric practice adopts a more individualized risk stratified and response adapted approach to salvage treatment with greater use of non-transplant salvage. Here, we present on behalf of the EuroNet Pediatric Hodgkin Lymphoma group, evidence and consensus-based guidelines for standardized diagnostic, prognostic and response procedures to allocate children and adolescents with R/R cHL to stratified salvage treatments.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005156
003      
CZ-PrNML
005      
20200528112755.0
007      
ta
008      
200511s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/HS9.0000000000000329 $2 doi
035    __
$a (PubMed)32072145
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Daw, Stephen $u Children and Young People's Cancer Services, University College Hospital London, London, UK.
245    10
$a Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group / $c S. Daw, D. Hasenclever, M. Mascarin, A. Fernández-Teijeiro, W. Balwierz, A. Beishuizen, R. Burnelli, M. Cepelova, A. Claviez, K. Dieckmann, J. Landman-Parker, R. Kluge, D. Körholz, C. Mauz-Körholz, WH. Wallace, T. Leblanc,
520    9_
$a The objective of this guideline is to aid clinicians in making individual salvage treatment plans for pediatric and adolescent patients with first relapse or refractory (R/R) classical Hodgkin lymphoma (cHL). While salvage with standard dose chemotherapy followed by high dose chemotherapy and autologous stem cell transplant is often considered the standard of care in adult practice, pediatric practice adopts a more individualized risk stratified and response adapted approach to salvage treatment with greater use of non-transplant salvage. Here, we present on behalf of the EuroNet Pediatric Hodgkin Lymphoma group, evidence and consensus-based guidelines for standardized diagnostic, prognostic and response procedures to allocate children and adolescents with R/R cHL to stratified salvage treatments.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hasenclever, Dirk $u Institute of Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
700    1_
$a Mascarin, Maurizio $u AYA and Pediatric Radiotherapy Unit, Centro di Riferimento Oncologico, Aviano, Italy.
700    1_
$a Fernández-Teijeiro, Ana $u Unit of Pediatric Onco-Hematology, Hospital Universitario Virgen Macarena, Seville, Spain.
700    1_
$a Balwierz, Walentyna $u Department of Pediatric Oncology and Hematology, Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland.
700    1_
$a Beishuizen, Auke $u Prinses Máxima Centrum voor Kinderoncologie, Utrecht, The Netherlands.
700    1_
$a Burnelli, Roberta $u Section of Pediatrics, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy.
700    1_
$a Cepelova, Michaela $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Czech Republic.
700    1_
$a Claviez, Alexander $u University Hospital Schleswig Holstein, Department of Pediatric and Adolescent Medicine, Pediatric Hematology, Oncology and Stem Cell Transplantation, Kiel, Germany.
700    1_
$a Dieckmann, Karin $u Department of Radiation Oncology, Medical University of Vienna, Vienna.
700    1_
$a Landman-Parker, Judith $u Service d'Hématologie et d'Oncologie Pédiatrique, Hôpital Armand Trousseau, Paris.
700    1_
$a Kluge, Regine $u Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany.
700    1_
$a Körholz, Dieter $u Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, Gießen, Germany.
700    1_
$a Mauz-Körholz, Christine $u Pädiatrische Hämatologie und Onkologie, Zentrum für Kinderheilkunde der Justus-Liebig-Universität Gießen, Gießen, Germany.
700    1_
$a Wallace, William Hamish $u Department of Pediatrics, Royal Hospital for Sick Children, Edinburgh, Scotland, UK.
700    1_
$a Leblanc, Thierry $u University of Edinburgh and Department of Pediatrics, Royal Hospital for Sick Children, Edinburgh, Scotland, UK.
773    0_
$w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 4, č. 1 (2020), s. e329
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32072145 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200528112753 $b ABA008
999    __
$a ind $b bmc $g 1524086 $s 1095211
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 4 $c 1 $d e329 $e 20200110 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace